Synonyms: compound 32 [PMID: 26861551]
Compound class:
Synthetic organic
Comment: GSK2245035 is reported as a selective Toll-like receptor 7 (TLR7) agonist, with potential clinical action as an intranasally administered anti-asthmatic [2]. It is Example 22 claimed in patent WO2010018133 [3].
The TLR7- IFNα pathway is a novel pathway being investigated for pharmacological intervention in allergic asthma. |
|
Bioactivity Comments |
In vivo findings disclosed in WO2010018133 report that GSK2245035 (Example 22) induces IFNα production, with mean serum levels reaching 21029 pg/ml (none detected in control mice) [3]. Early clinical trial results show clear target engagement at a dose of 20ng (as detected by local and peripheral increase of IFN-gamma-inducible protein-10) and an accceptable safety profile doses acheiving a local TLR7-mediated immune response [6]. Doses above 100ng were associated with undesireable cytokine release syndrome-related symptoms. Direct binding assays have not been performed for this compound, rather its engagement with TLR7 has been assessed in functional assays measuring ligand-induced increases in downstream cytokine production/release [2]. An EC50 of ~4.5nM for IFNα production in PBMCs is reported [2]. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|